Carcinoma, Neuroendocrine clinical trials
The registry lists 172 studies for Carcinoma, Neuroendocrine across more than 10 countries. 66 are recruiting or about to start. 112 of them are mainly about Carcinoma, Neuroendocrine (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its 4 narrower conditions too, such as Carcinoma, Merkel Cell: 498 studies, 135 open.
Get an email when these change. Save the Carcinoma, Neuroendocrine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
National Cancer Institute (NCI) (12) · M.D. Anderson Cancer Center (8) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (7) · Peking University (6) · Peking Union Medical College Hospital (6) · European Institute of Oncology (4) · Tianjin Medical University Cancer Institute and Hospital (4) · SCRI Development Innovations, LLC (3)
What is being tested here
Drugs under test in Carcinoma, Neuroendocrine studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Alveltamig | 5 | 1 | 5 |
| Nilvanstomig | 3 | 1 | 3 |
| AMG 757 | 3 | 1 | 3 |
| Surufatinib | 2 | 0 | 3 |
| Fluorodeoxyglucose F18 | 2 | 0 | 2 |
| Irinotecan | 1 | 0 | 4 |
| Atezolizumab | 1 | 0 | 3 |
| Sintilimab | 1 | 0 | 3 |
| Dostarlimab | 1 | 0 | 2 |
| Fluorouracil | 1 | 0 | 2 |
Drug classes tested here Immune checkpoint inhibitors 9 open · Tyrosine kinase inhibitors (TKIs) 4 open · Antimetabolites 1 open · HDAC inhibitors 1 open · Alkylating agents 6
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Nov 2026First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma · Peking Union Medical College Hospital
- Dec 2026Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Dec 2026Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types · University of Florida
- Dec 2026Immunotherapy in Neuroendocrine Carcinoma of the Cervix · Peking Union Medical College Hospital
- Dec 2026Multi-omics Study of Cervical Neuroendocrine Carcinoma · Peking Union Medical College Hospital
- Dec 2026A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma · Nanjing Leads Biolabs Co.,Ltd
- Dec 2026A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma · Beijing GoBroad Hospital
- Dec 2026DLL3-Targeted PET/CT in Neuroendocrine Carcinoma · The First Affiliated Hospital of Xiamen University
- Dec 2026YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs. · European Institute of Oncology
- Dec 2026A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Tianjin Medical University Cancer Institute and Hospital
Who these studies take
Of the 47 Carcinoma, Neuroendocrine studies recruiting now, 30 (64%) set no upper age limit and 10 (21%) stop at 75 or younger. 2 (4%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (2%) | 1 (2%) |
| 18 | 45 (96%) | 45 (96%) |
| 30 | 47 (100%) | 47 (100%) |
| 40 | 46 (98%) | 46 (98%) |
| 50 | 46 (98%) | 46 (98%) |
| 65 | 46 (98%) | 46 (98%) |
| 75 | 44 (94%) | 44 (94%) |
| 85 | 35 (74%) | 35 (74%) |
Across all 172 studies, recruiting or not: 13% stop at 75 or younger and 1% at 65; 8% take children; 1% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Carcinoma, Neuroendocrine studies take
Of 43 phase 2 interventional studies under Carcinoma, Neuroendocrine, half reached primary completion within 69 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 2 | 69 mo50–91 · 43 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting1
Studies
Recruiting first, then most recently updated. Showing 50 of 172. Browse all 172 → or search them.
- A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and ToxicityRecruitingNCT06406465Phase 21 country
- Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsRecruitingNCT07080242Phase 13 countries
- Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)RecruitingNCT052379341 country
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the LungRecruitingNCT05058651Phase 2/31 country
- A Study of Armored CAR T Cells in People With CancerRecruitingNCT07783477Phase 11 country
- Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine NeoplasmsRecruitingNCT07684170Phase 21 country
- A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath TumorsRecruitingNCT06041516Phase 11 country
- A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and ProstateNot yet recruitingNCT06941480Phase 11 country
- Immunotherapy in Neuroendocrine Carcinoma of the CervixNot yet recruitingNCT079114231 country
- Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory DiseaseRecruitingNCT07509034Phase 11 country
- A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)RecruitingNCT06330064Phase 1/218 countries
- QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine CarcinomaNot yet recruitingNCT07894211Phase 3
- Oxaliplatin-Based Adjuvant Therapy for Gastrointestinal Neuroendocrine Carcinoma**Enrolling by invitationNCT078915721 country
- TheraSphere Japan Pre-Market StudyRecruitingNCT07377487Not applicable1 country
- Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid TumorsRecruitingNCT07278479Phase 1/21 country
- Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung CancerRecruitingNCT06283719Phase 1/21 country
- A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NECNot yet recruitingNCT07720193Phase 31 country
- A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)RecruitingNCT07488923Phase 11 country
- Multi-omics Study of Cervical Neuroendocrine CarcinomaNot yet recruitingNCT078793391 country
- TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid TumorsRecruitingNCT07713732Phase 11 country
- DLL3-Targeted PET/CT in Neuroendocrine CarcinomaRecruitingNCT07458906Not applicable1 country
- ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07833839Phase 31 country
- Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)RecruitingNCT06816394Phase 21 country
- Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin AmericaRecruitingNCT071929914 countries
- A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the LungNot yet recruitingNCT07561645Phase 2
- The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]RecruitingNCT026888941 country
- Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine CarcinomaNot yet recruitingNCT07738159Phase 2
- AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine CancerNot yet recruitingNCT07712094Phase 21 country
- A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)RecruitingNCT05652686Phase 1/21 country
- A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.RecruitingNCT05747729Phase 1/21 country
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesRecruitingNCT05000294Phase 1/21 country
- A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerRecruitingNCT07174583Phase 1/21 country
- A Phase I Study of HS-20108 in Participants With Advanced Solid TumorsRecruitingNCT06936735Phase 11 country
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRecruitingNCT03093116Phase 1/219 countries
- A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07595913Phase 31 country
- SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)RecruitingNCT06889493Phase 11 country
- Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma PatientsRecruitingNCT06893783Phase 21 country
- A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07520357Phase 21 country
- Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine CarcinomaRecruitingNCT07518602Phase 21 country
- A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NECNot yet recruitingNCT07510594Phase 21 country
- A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine CarcinomaRecruitingNCT06157827Phase 1/21 country
- CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine TumorsRecruitingNCT074298511 country
- Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)RecruitingNCT06937905Phase 31 country
- Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)Not yet recruitingNCT07337447Phase 21 country
- ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingNCT07038096Phase 1/21 country
- Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingNCT05978284Phase 1/21 country
- A Study of MT-4561 in Patients With Various Advanced Solid TumorsRecruitingNCT06943521Phase 1/22 countries
- Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSIRecruitingNCT06333314Phase 21 country
- RegisterNET - A Registry for Neuroendocrine Tumors in the USA and WorldwideEnrolling by invitationNCT022705671 country
- Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown PrimaryRecruitingNCT04325425Phase 21 country